
    
      The study is designed with single-arm, open-label phase (SAOL) of Tadekinig alfa treatment
      duration for 18-week followed by an 8-week Randomized Withdrawal (RW) period for efficacy and
      safety evaluation, with no interruption between the two phases of treatment. The screening
      period will occur before the SAOL phase and before the first dose of Investigational
      Medicinal Product (IMP)
    
  